Search is Powered by Google
Cancer / Oncology News

Texas Voters OK 3 Billion Dollars In New Cancer Funding

Main Category: Cancer / Oncology
Article Date: 08 Nov 2007 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Texans' 61% support on Tuesday for a commitment to provide $3 billion in funding for cancer research over the next ten years is a clear signal to researchers, investors and cancer advocates that Texas will be a major focal point of activity in the next phases of the fight against the disease, according to BioHouston CEO Jacqueline Northcut.

"When this commitment is leveraged 100% with matching funds from the grant recipients, the total $6 billion effect will be one-fifth larger than the entire National Cancer Institute annual budget and a watershed point in the state's emergence as a life science center," Northcut said. The new funding will be an addition to the $1.5 billion in annual life science research conducted in the Houston region that has helped to double the number of life science companies in the region to more than 130, she noted.

"This new cancer prevention and research funding will help us recruit internationally recognized leaders to Texas, to stimulate collaborations between universities, to take on new initiatives and approaches, and to support the training of future researchers and physicians," Northcut predicted.

The measure approved by Texas voters Tuesday creates the Cancer Prevention and Research Institute of Texas and authorizes the Institute to issue up to $300 million per year in bonds to fund cancer research grants, research facilities, and cancer prevention and control programs. Not more than 5% of total grant awards can be used for facility construction, and not more than 10% for prevention and control programs. The focus of the Institute's activities will be on institutions, facilities, research, and programs in Texas.

At a recent BioHouston conference for venture capitalists and life science start-up companies, Texas Governor Rick Perry noted that more than 77,000 Texans develop cancer each year, and described the disease as the state's number-two killer, ending the lives of more than 35,000 Texans annually. As a result of funding the new Institute, Perry predicted, "We're going to lure some of the brightest minds -- there are going to be people that never thought ten or 15 years ago that they'd be living in the Lone Star State."

BioHouston is a non-profit organization founded by Houston-region academic/research institutions to lead the effort to establish the Houston region as a vigorous global competitor in life science and biotechnology commercialization.

http://www.biohouston.org




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...